Alzheimer’s disease affects more than 35 million people, a number that is expected to increase in the coming years. Currently, Alzheimer’s diagnoses rely on clinical neuropathologic assessment of amyloid-? peptide aggregates (plaques) and neurofibrillary tangles. But now researchers reveal that an enzyme already implicated in a host of neural disorders could someday serve as a biomarker.
from Top Health News – ScienceDaily http://bit.ly/2gbW63c
from Tumblr http://bit.ly/2gVBn7D
No comments:
Post a Comment